Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03067441 · ClinicalTrials.gov registry record · Phase 3
Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)
A Phase 3 study, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,462
- Enrollment target
NCT03067441 is a Phase 3 study that has completed, run by Esperion Therapeutics. The registered enrollment target is 1,462 participants.
The verdict
NCT03067441, a Phase 3 study, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,462 participants
- Enrollment target
Study Summary
The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
Interventions
- DRUG bempedoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,462 participants |
| Start Date | 2017-02-03 |
| Est. Completion | 2019-11-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03067441
The ClinicalTrials.gov registry entry for NCT03067441 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,462 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esperion Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bempedoic acid is the first listed.
NCT03067441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03067441 about?
NCT03067441 is a clinical study titled "Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)". The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
What is the current status of trial NCT03067441?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,462 participants. The study started on 2017-02-03. Estimated completion is 2019-11-05.
What interventions are being tested in trial NCT03067441?
The interventions under investigation include: bempedoic acid (DRUG).
Who is sponsoring clinical trial NCT03067441?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.